Profound Medical Corp (PROF)

Profound Medical Corp.'s stock price has increased over the past six months. The stock price rose by 13.59% in the past month and 43.78% over the last three months, with a year-to-date return of 7.24% and a 12-month increase of 11.49%. As of January 9, 2026, the share price was $8.44, an increase from $7.45 on January 13, 2025. Recent corporate activities include the closing of a private placement and a registered direct offering in December 2025. Johns Hopkins Hospital treated its first commercial prostate cancer patient using the TULSA-PRO system on January 6, 2026. Profound Medical reported its Q3 2025 earnings on November 13, 2025, with revenue of $5.3 million, an 87% increase year-over-year, and a gross margin of 74.3%. The company also launched its TULSA-AI Volume Reduction software at the RSNA annual meeting.

Analysis of Profound Medical Corp.'s seasonal charts over the past five years suggests a potential seasonal strength period with a "Buy Date" of November 29 and a "Sell Date" of February 27. This timeframe has shown positive results compared to the S&P 500 Total Return Index in four out of five periods, with an average return of 35.4% above the benchmark. However, only five years of data are available, which may be insufficient to create a fully reliable seasonal profile. This seasonal timeframe correlates poorly with the broader Healthcare sector's period of seasonal strength, which typically runs from April 25 to December 4.

Profound Medical Corp. is a commercial-stage medical device company in the Healthcare sector, specifically the Medical Devices industry. The company develops and markets incision-free therapeutic systems for image-guided ablation of diseased tissue. Its flagship product, the TULSA-PRO system, integrates MRI, robotically driven transurethral thermal ultrasound, and closed-loop temperature feedback control to ablate malignant or benign prostate tissue. The TULSA-PRO procedure treats localized prostate cancer, benign prostatic hyperplasia (BPH), and radio-recurrent localized prostate cancer. The company also offers Sonalleve, a therapeutic platform that combines real-time MRI and thermometry for treating uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and benign tumors.

Profound Medical Corp. markets its incision-free therapeutic systems in Canada, Germany, the United States, and Finland. The company has a network of clinical partners and distributors across North America and Europe.

Profound Medical's brand reputation has been positively influenced by the TULSA-PRO system gaining traction, with Johns Hopkins Medicine treating its first commercial case in January 2026. The Hong Center Scottsdale achieved a world-first milestone of 200 independent TULSA Procedures performed by a urologist without radiologist involvement in November 2025. Profound Medical received recognition at the RSNA for perioperative data from the CAPTAIN randomized controlled trial in December 2025. The launch of the AI-powered TULSA-AI Volume Reduction software further contributes to a positive reputation. The company's financial health has been in the "Green zone" for over three months, indicating a strong uptrend.

Profound Medical is owned by 36.64% institutional shareholders, 1.94% Profound Medical insiders, and 61.41% retail investors. As of September 30, 2025, 49 institutional owners and shareholders held a total of 12,006,093 shares. Major institutional shareholders include FIL Ltd, Gagnon Securities LLC, Letko, Brosseau & Associates Inc., Gagnon Advisors, LLC, Royce & Associates LP, Rosalind Advisors Inc., Timelo Investment Management Inc., MMCAP International Inc. SPC and Royal Bank Of Canada. The largest individual shareholder is Arun Swarup Menawat, who owns 587,089 shares, representing 1.94% of the company.